MYM Nutraceuticals Inc. vs. My Marijuana Inc.
Thread abonnieren
|
--button_text--
interessant
|
|
witzig
|
|
gut analysiert
|
|
informativ
|
0
MYM Enters Into Asset Purchase and Consulting Agreement with "Mary Jane's Touch"
Mittwoch, 06.09.2017 11:30 von PR Newswire
PR Newswire
VANCOUVER, British Columbia, Sept. 6, 2017
VANCOUVER, British Columbia, Sept. 6, 2017 /PRNewswire/ --MYM Nutraceuticals Inc., (MYM.CN) (CSE: MYM.CN) (OTC: MYMMF) (the "Company" or "MYM") is pleased to announce it has entered into an asset purchase and consulting agreement with "Mary Jane's Touch" (MJT). MJT manufactures and distributes cannabidiol (CBD) products and possesses numerous formulations of CBD products and research on CBD.
Under the agreement, MYM will acquire all of MJT's intellectual property regarding CBD, including all formulas, recipes, and research regarding the extraction and production of MJT's CBD products. MYM is also purchasing MJT's database of suppliers, clients and customers, both current and potential.
In exchange for the assets and consulting services, MYM shall pay MJT: a consulting fee of $125,000 CDN per annum as long as services are delivered; a total of 500,000 MYM common shares at a price of $0.45, which will be subject to a contractual restriction in that 125,000 shares will become free-trading every 6 months over the first two years of the consulting term; a total of 250,000 options to purchase MYM common shares at a price of $0.45, vesting every six months over the 5-year consulting term; 1% commission on the first $500,000 of gross sales of CBD products, and 0.5% thereafter produced within the production facilities.
"This is an exciting acquisition for MYM and its shareholders," said Rob Gietl, MYM's CEO. "Acquiring the 'Mary Jane's Touch' product lines and expertise will expedite the transition of 'HempMed' into MYM's new brand of CBD products – 'Joshua Tree'. The agreement will enable Joshua Tree to rapidly develop and expand on its line of innovative CBD nutraceutical products".
About MYM
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
"Rob Gietl"
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
MYM Investor Relations Contact:
Terry Brown – 1 (855) 696-2261
You can email Mr. Brown here: http://www.mymarijuana.ca/contact-us/
View original content:http://www.prnewswire.com/news-releases/...janes-touch-300514454.html
SOURCE MYM Nutraceuticals Inc.
Optionen
0
0
"Im Gegenzug für die Vermögenswerte und Beratungsleistungen zahlt MYM MJT: eine Beratungsgebühr von $ 125.000 CDN pro Jahr, solange Dienstleistungen erbracht werden; insgesamt 500.000 MYM-Stammaktien zu einem Preis von 0,45 US-Dollar, die einer vertraglichen Beschränkung unterliegen werden, da 125.000 Aktien in den ersten beiden Jahren der Beratungsfrist alle 6 Monate freihandel werden; insgesamt 250.000 Optionen zum Kauf von MYM-Stammaktien zu einem Preis von 0,45 $, die alle sechs Monate über die 5-jährige Beratungsfrist ausgeübt werden; 1% Provision auf den ersten $ 500.000 der Bruttoverkäufe von CBD-Produkten und 0,5% danach in den Produktionsanlagen produziert."
Optionen
0
USA News Group -- North of the border in Canada, preparation for the great lifting of cannabis prohibition is also underway, as the country braces for legalization in July of 2018.
In August alone, Health Canada granted 4 separate Access to Cannabis for Medical Purposes Regulations (ACMPR) licences, raising the total in the country to 56. Companies making a mark in the industry include: Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF), Aphria Inc. (TSX: APH) (OTC: APHQF), AmeriCann, Inc. (OTC: ACAN), MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF)
And now the markets too are more than ready for the surge to come.
At one point in time, Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF) was the only cannabis stock access point to invest in, soaring to as high as $13 per share in February of 2017, only to fall more than 40% to under $8 in May of this year.
But even at an over $1.5 billion market cap, Canopy hasn't put its competitors too far in its dust.
Trailing not too far behind in the great cannabis growth race fellow pot powerhouses Aurora Cannabis (TSXV: ACB) (OTC: ACBFF), and Aphria Inc. (TSXV: APH) (OTC: APHQF) who are each closing in on the $1 billion market cap mark, and a relative newcomer to the race MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF), which is set to make a major splash in the coming year with one of the world's largest cannabis greenhouses, that dwarfs anything the country has seen so far.
GROW, BABY, GROW!
While the legal cannabis industry is still very much in its infancy, the sky is the limit on the value this sector can provide.
Beyond the plant's basic use through straight consumption, whether it's medicinal or recreational, are several other derivatives that provide major potential for the industry as a whole.
In particular is the Cannabidiol compound of the plant, better known as CBD. Used in all types of therapeutic products from topical ointments to beverages to food products, CBD-only products deliver much of the medicinal benefits of the cannabis plant, without the high that's typically attributed to cannabis' other product, THC.
Legal in all 50 US states (as well as in Canada), the American CBD market hit $170 million in 2016, and is projected to hit $1 billion by 2020, while the American marijuana industry as a whole is expected to hit $50 billion by 2026.
In order to get to that milestone, however, growth capabilities are going to need to expand, and quite rapidly.
RISE OF THE MEGA GREENHOUSE
Much like in the construction industry's competitive race to build 'megastructures', so too is there an ongoing race to build the biggest and best greenhouses in the world.
The world's largest marijuana greenhouse distinction currently goes to Canopy's Tweed facility in Niagara-on-the-Lake, Ontario, which covers 350,000 square feet of greenhouse space.
However, Canopy's competitors at Aurora Cannabis began work on their Leduc facility near the Edmonton Airport, which was to be more than double the size, clocking in at 800,000 square feet of growing space. A facility of that size is capable of 100,000 kgs of cannabis annually.
Set to surpass Aurora's behemoth is AmeriCann Inc. (OTC: ACAN), which announced its plans to build the largest cannabis greenhouse facility in the USA at roughly 1 million square feet, to be located in Massachusetts.
But, like a mega tower that's set to be the tallest in the world, but is surpassed even in the planning stage by an even greater monolith, along comes MYM.
MYM Nutraceuticals and its majority-owned subsidiary CannCanada signed an exclusive deal with the aptly-named Quebec municipality of Weedon, to build a 1.5 million-square-foot cannabis production facility, consisting of fifteen 100,000-square-foot-greenhouses.
This massive marijuana operation will be one of the largest grow operations on the planet, with the potential to produce over 150,000 kgs of cannabis per year-or roughly $750,000,000 annually.
MYM'S MAJOR MOVE
The project in Weedon is unique to the industry, as it's the first time a cannabis producer has worked in tandem with a municipality to create jobs and spark an entire industry in the process.
As it is laid out, the plans will have Weedon itself acquiring the 329 acres of land for MYM to construct upon.
The deal was originally signed between the municipality and CannaCanada. MYM went on to acquire 75% of CannaCanada, and is set to earn an additional 15% to take it to 90% ownership upon completion.
Both the architectural and security plans for Phase One of the Weedon project are complete, which will account for the first 300,000 square feet of greenhouse space, with another four phases still in development.
Along with the Weedon facility, MYM has advanced on another Quebec-based project, with the recent approval and permitting to begin construction on the company's smaller facility in Laval. Phase one of construction for the Laval facility is scheduled for completion by the end of Q4 2017, with the capability of producing 1,000 kgs of cannabis annually.
Through integration, MYM is diversified across much of the cannabis sector, from growth, to formulation and production, to branding and distribution.
At this point it has many of the tools in place to leap into that of a major status among the Auroras, Aphrias, and Canopys of the world. While those companies range from $800 million to $1.5 billion in market caps, MYM Nutraceuticals remains undervalued at a roughly $27 million market cap.
MYM's operations are spread across its assets, ranging from CannaCanada in Weedon, to its other LP subsidiary Sublime in Montreal, to its products and branded entities Joshua Tree, MyHemp Skin Therapy, and HempMed.
Still relatively new to the market, MYM has more than doubled its value since it began trading in March of this year. Acting as an umbrella for several cannabis-related outlets, MYM Nutraceuticals appears to be in line for a promotion to a bigger board in the coming quarters.
POTENTIAL COMPARABLES
Aphria (TSXV: APH) (OTC: APHQF)
Aphria Inc., boasts itself as one of Canada's lowest cost producers, that produces, supplies and sells medical cannabis. Located in the greenhouse capital of Canada, Leamington, Ontario, Aphria provides pharma-grade medical cannabis, and quality patient care. Aphria was the first public LP to report positive cash flow from operations, and the first to report positive earnings in consecutive quarters.
Aurora Cannabis (TSXV: ACB) (OTC: ACBFF)
Through its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., Aurora Cannabis is a major LP, operating a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta. Aurora made waves when it announced the construction of its 800,000 square foot "Aurora Sky" facility second 800,000 square foot production facility at the Edmonton International Airport. Aurora's also involved in Quebec, with its third 40,000 square foot production facility set to be completed in Pointe-Claire, Quebec, on Montreal's West Island. Aurora also holds a minority stake in leading extraction technology company Radient Technologies Inc., based in Edmonton, and a minority stake in Australian company Cann Group Limited, which was the first in Australia to conduct research on and cultivate medical cannabis. Aurora also owns German wholesale importer, exporter, and EU medical cannabis distributor Pedanios.
Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF)
The granddaddy of the corporate cannabis sector, Canopy Growth is the world's largest diversified cannabis company. Canopy boasts a wide offering of distinct brands and curated cannabis varieties in dried, oil and capsule forms. Most widely recognized is Canopy's subsidiary Tweed which is the world's most recognized marijuana production brand, as well as an industry educator. Accompanying Tweed in Canopy's portfolio is medical-grade cannabis producers Bedrocan Canada. In total, Canopy Growth's numerous state-of-the-art production facilities total over half a million square feet of GMP-certified indoor and greenhouse production capacity.
For a more in-depth look into MYM you can view the in-depth report at USA News Group from last week: http://usanewsgroup.com/2017/08/29/...-in-the-marijuana-stock-boom-2/
Article Source:
USA News Group
http://usanewsgroup.com
info@usanewsgroup.com
Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice. USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
DISCLAIMER: USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
E-mail: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
SOURCE USA News Group
Optionen
0
0
Canadian Securities Exchange Launches CSE25 Index
Toronto, Ontario--(Newsfile Corp. - September 18, 2017) - The Canadian Securities Exchange ("CSE") is pleased to announce the introduction of a new index comprised of the securities of the largest companies trading on the exchange.
The CSE25 Index is a subgroup of the CSE Composite Index. The composite index launched in 2015 and includes almost half of the exchange's listed companies and covers over 75% of the trading activity on the exchange. The new index includes the top twenty-five securities by market capitalization contained in the composite index. These companies account for over 50% of the weighting in the larger index and are typically stocks that attract considerable trading volume.
Richard Carleton, CEO, observed that "as the exchange has grown rapidly in terms of trading volumes and market capitalization it is appropriate that we give market participants a benchmark that monitors the performance of our largest and most liquid issues. As the 'exchange for entrepreneurs' we are proud of their success in the Canadian capital markets."
Trading volumes on the CSE have been exceptionally robust in 2016 and 2017. The turnover of the entire market measured by the value of trading divided by the total market cap has averaged 6.6% per month in the year to date, which represents a level of market activity unrivalled in the Canadian exchange space.
A complete list of the constituent securities of the CSE25 Index appears below.
Symbol Security Name CSE 25 Weighting
LHS Liberty Health Sciences Inc. 14.31%
TRST CannTrust Holdings Inc. 13.00%
URB.A Urbana Corporation A NV 6.25%
AHG Alternate Health Corp. 5.69%
MARI Maricann Group Inc 5.13%
CRZ CannaRoyalty Corp. 4.90%
BCC The Canadian Bioceutical Corporation 4.11%
MDM Marapharm Ventures Inc 3.96%
URG Oriental Non-Ferrous Resources Development Corp. 3.68%
GLH Golden Leaf Holdings Ltd. 3.56%
XMG MGX Minerals Inc. 3.13%
FLT Drone Delivery Canada Corp. 2.99%
THC THC Biomed Intl Ltd 2.88%
ISOL Isodiol International Inc. 2.82%
IN InMed Pharmaceuticals Inc. 2.76%
BLO Cannabix Technologies Inc. 2.54%
N Namaste Technologies Inc. 2.22%
IAN iAnthus Capital Holdings Inc. 2.22%
VGW Valens Groworks Corp. 2.22%
MTA Metalla Royalty and Streaming Ltd. 2.15%
SNA Star Navigation Systems Group Ltd. 2.02%
LDS Lifestyle Delivery Systems Inc 1.95%
MYM MYM Nutraceuticals Inc. 1.91%
MRM Micromem Technologies Inc. 1.81%
RSS RESAAS Services Inc. 1.80%
Optionen
0
0
1
2
3
4
5
Average Rating 5
September 26, 2017 1,497 Views
Vancouver, B.C., September 26, 2017 MYM Nutraceuticals Inc., (CSE: MYM) (the Company or MYM) is pleased to announce a non-brokered private placement of up to 6,000,000 units at a price of CAD$0.50 per unit.
Each unit will consist of one common share and one transferable share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share exercisable for a period of twelve months following the closing of the private placement at a price of CAD $1.00 per warrant share.
The private placement is subject to the approval of the Canadian Securities Exchange and the securities will be subject to a four-month and one day hold period under securities laws.
The Company intends to use the net proceeds from the private placement for general working capital and corporate purposes.
Optionen
0
0
0
Posted at 10:25h in News by Dan Schmink
Currently, all cannabinoids are prohibited in-competition by WADA. However, that is all about to change! The World Anti Doping Agency announced this Friday that CBD will no longer be banned from use in 2018.
“Cannabidiol is no longer prohibited,” WADA wrote on its website. “Synthetic cannabidiol is not a cannabimimetic; however, cannabidiol extracted from cannabis plants may also contain varying concentrations of THC, which remains a prohibited substance.”
In 2016, When Nick Diaz was given a public warning by USADA, after he mentioned he was vaping “CBD oil.” The conversation about cannabis, instantly became a hot topic in the athletic community. Immediately announcing their investigation into Diaz’s admitted use of the substance, it was later confirmed he passed in-competition blood and urine samples prior to use of the vape pen.
Quelle:
http://www.mmanews.com/cbd-no-longer-prohibited-by-wada-from-2018/
Optionen
0
( sh. die Homepage, Zahlen, Daten , Fakten von MYM von heute )
340.000.000 Mio Dollar Umsatz in 2019 geplant !! WOW !
Wenn diese Summe nur halbwegs richtig eintrifft - wird MYM wohl mittelfristig in
einen Bewertungsbereich von 1-2 Mrd. Dollar bis 2019 kommen.
Bei ca. 80 Mio Aktien z.Zt. würde das per Heute einen Kurs je MYM-Aktie
von 20 Dollar bedeuten...alles unglaublich.....ich weiß.......aber in 12-24 Monaten
werden wir schlauer sein.
Optionen
0
1
MYM expandiert mit seinen Marihuanabetrieben weltweit, aber nicht in die USA
Vancouver, B.C., 20. Oktober 2017 - Wie bereits am 18. Oktober 2017 angekündigt, freut sich MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF) (das Unternehmen oder MYM) sehr darüber, nun eine Marktgröße in der aufstrebenden Marihuanabranche Australiens zu sein. Gleichzeitig fühlt sich das Unternehmen veranlasst, seine Haltung in Bezug auf Marihuanabetriebsstätten in den Vereinigten Staaten klarzustellen.
Die Führungskräfte, Berater und Rechtsanwälte von MYM sind konsequent der Meinung, dass Marihuanaprojekte in den Vereinigten Staaten äußerst riskant seien, weil Marihuana dort in die Kategorie der Schedule I-Narkotika, gleich neben Heroin und Kokain, gereiht wird und somit auf US-Bundesebene illegal ist. Die US-Bundesgesetze zu Marihuana könnten jederzeit umgesetzt werden und dies würde kanadische Unternehmen, die in den USA im Marihuanageschäft tätig sind, in Gefahr bringen; man könnte sie strafrechtlich verfolgen und ihre Aktiva beschlagnahmen. Die Anklage könnte auf Drogenhandel, Besitz von Narkotika, Geldwäsche, Beteiligung an Aktivitäten des organisierten Verbrechens etc. lauten. Aus besagten Gründen hat MYM viele Geschäftsangebote in den USA, die an das Unternehmen herangetragen wurden, abgelehnt.
Unsere Haltung wird zusätzlich dadurch untermauert, dass von der kanadischen Wertpapieraufsicht (Canadian Securities Administrators/CSA) am 16. Oktober 2017 eine Personalmitteilung an alle börsennotierten Unternehmen mit Betriebsstandorten in den Vereinigten Staaten übermittelt wurde. Wir erwarten, dass Emittenten, die in den USA im Rahmen ihrer Geschäftstätigkeit mit Marihuana zu tun haben, in ihren Offenlegungen auf das aktuelle rechtliche und regulatorische Umfeld hinweisen, auch auf Risiken, die aus Änderungen in der Umsetzung der US-Bundesgesetze resultieren, erklärt Louis Morisset, Chair und President von CSA und CEO von Autorité des marchés financiers.
Die Offenlegungskriterien der CSA gelten für alle Emittenten, die in den USA im Rahmen ihrer Geschäftstätigkeit mit Marihuana zu tun haben. Dazu zählen auch jene, die direkt und indirekt in die Aufzucht und den Vetrieb von Marihuana involviert sind, sowie Emittenten, die ihre Güter und Dienstleitungen Dritten anbieten, die im US-Marihuanageschäft aktiv sind. Von den Emittenten wird erwartet, dass sie diese Informationen in Prospekteinreichungen und anderen erforderlichen Dokumenten, wie z.B. im Jahresbericht und in den Erläuterungen und Analysen des Managements (MD&A), offenlegen. Die Börsenaufsicht der Toronto Stock Exchange (TSX) erklärte, dass sie die Unternehmen bis Ende des Jahres prüfen und jene, welche die Auflagen nicht erfüllen, von der Börse nehmen wird.
Seit Donald Trump und die Republikaner ins Weiße Haus eingezogen sind, machen sie die von Präsident Obama in der Marihuanabranche erzielten Fortschritte sukzessive zunichte. In jüngster Zeit hört man immer rauere und lautere Töne über Marihuana. Das Justizministerium unter Generalstaatsanwalt Jeff Sessions hat sämtliche Forschungsaktivitäten in Zusammenhang mit Marihuana zum Erliegen gebracht. Von Sessions werden auch Aussagen zitiert wie Gute Menschen rauchen kein Marihuana und Marihuana ist annähernd so abscheulich wie Heroin. Der medizinische Nutzen wird von ihm völlig negiert. Chuck Rosenberg, der amtierende Chef der US-Antidrogenbehörde DEA, erklärte am Donnerstag, dass Marihuana kein Medikament sei. Damit kommen auf Marihuana in den kommenden Jahren düstere Aussichten zu, denn viele Fortschritte, die unter Obama erreicht wurden, könnten rückgängig gemacht werden.
MYM bereitet allerdings den Markteinstieg seiner CBD-Produktlinie Joshua Tree in den Vereinigten Staaten vor; denn CBD ist keine psychoaktive Substanz und in den USA daher legal. Die Marke Joshua Tree wird voraussichtlich Anfang 2018 auf den Markt kommen.
Auch wenn die Marihuanabranche in den USA in den kommenden drei Jahren möglicherweise größere Rückschläge erleiden könnte, sind dies großartige Neuigkeiten für kanadische Cannabisfirmen wie MYM. Das Unternehmen kann hier in Kanada und in Australien in einem Umfeld, in dem Cannabis komplett legal ist, unbehindert wachsen. In den USA gibt es eine Menge an nicht investiertem Kapital, weil die US-Bundesgesetze keine Investitionen in illegale Unternehmen zulassen. Dadurch blicken immer mehr Anleger in Richtung Norden. Große Organisationen, Fonds und Investmentbanken wollen in das legale Cannabisgeschäft investieren. Es gibt weltweit nur zwei Länder, in denen Cannabis legalisiert wurde: Kanada und Australien. MYM steht mit zahlreichen amerikanischen Konzernen in Gesprächen, die daran interessiert sind, MYM-Projekte zu finanzieren.
Optionen
1
Vancouver, B.C., 23. Oktober 2017 MYM Nutraceuticals Inc., (CSE: MYM) (das Unternehmen oder MYM) freut sich, den Abschluss der ersten Tranche seiner Privatplatzierung ohne Brokerbeteiligung bekannt zu geben, in deren Rahmen 5.709.000 Einheiten zum Preis von 0,50 $ pro Einheit begeben wurden und daraus ein Bruttoerlös in Höhe von 2.854.500 $ erzielt wurde. Jede Einheit der Privatplatzierung besteht aus einer Stammaktie und einem übertragbaren Aktienkaufwarrant, wobei jeder Warrant innerhalb eines Jahres in eine zusätzliche Stammaktie zum Preis von 1,00 $ eingetauscht werden kann. Die Wertpapiere unterliegen laut Wertpapierrecht einer Haltedauer von vier Monaten plus einem Tag. Im Rahmen der Finanzierung wurden Provisionen (Finder's Fees) in Höhe von insgesamt 102.570,83 $ bezahlt. Insider haben 566.250 Einheiten der ersten Tranche der Privatplatzierung gezeichnet. Das Unternehmen hat die Absicht, den Nettoerlös aus der Privatplatzierung als Betriebskapital bzw. für Unternehmenszwecke zu verwenden.
Optionen
0
Zum Vergleich:
Canopy Growth Aktie & Unternehmen
Website www.canopygrowth.com
Aktienanzahl 171,1 Mio. (Stand: 19.09.17)
Marktkap. 2,73 Mrd. $
Meine Meinung:
MYM wird irgendwann die 1 Mrd Euro an Bewertung erreichen - und es Canopy gleich tun.
Würde ein Kursziel von 10-12 Euro bedeuten......
Bei Canopy Bewertung von Heute - 2,5 Mrd Euro = 25-30 Euro je MYM-Aktien.
Fehlt nur noch die Lizenz von ACMPR - dann geht das Feuerwerk bei MYM los........
Meinungen und Einschätzungen von euch zu MYM ??
Optionen
0
Optionen
| Antwort einfügen |
| Boardmail an "dan66" |
|
Wertpapier:
MYM Nutraceuticals
|
0
aber da jetzt die PP abgeschlossen ist, kann es schnell auf die höhe von 1 CAD (preis pro warrant) gehen.
dazu kommt das die insider schon 100erttausende akteien gezogen haben also ihre warrants, zu 1 CAD.
Im ganzen Oktober gab es nur "Käufe"
https://www.canadianinsider.com/...h=MYM%20%7C%20MYM%20Nutraceuticals